- Home
- NTRA vs ZBH Comparison
NTRA vs ZBH Comparison
Compare NTRA & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- ZBH
- Stock Information
- Founded
- NTRA 2003
- ZBH 1927
- Country
- NTRA United States
- ZBH United States
- Employees
- NTRA N/A
- ZBH N/A
- Industry
- NTRA Medical Specialities
- ZBH Industrial Specialties
- Sector
- NTRA Health Care
- ZBH Health Care
- Exchange
- NTRA Nasdaq
- ZBH Nasdaq
- Market Cap
- NTRA 21.7B
- ZBH 19.1B
- IPO Year
- NTRA 2015
- ZBH N/A
- Fundamental
- Price
- NTRA $163.02
- ZBH $102.81
- Analyst Decision
- NTRA Strong Buy
- ZBH Hold
- Analyst Count
- NTRA 16
- ZBH 20
- Target Price
- NTRA $193.50
- ZBH $112.39
- AVG Volume (30 Days)
- NTRA 1.7M
- ZBH 1.8M
- Earning Date
- NTRA 08-07-2025
- ZBH 08-07-2025
- Dividend Yield
- NTRA N/A
- ZBH 0.93%
- EPS Growth
- NTRA N/A
- ZBH N/A
- EPS
- NTRA N/A
- ZBH 4.11
- Revenue
- NTRA $1,964,250,000.00
- ZBH $7,833,800,000.00
- Revenue This Year
- NTRA $19.98
- ZBH $7.64
- Revenue Next Year
- NTRA $16.16
- ZBH $5.64
- P/E Ratio
- NTRA N/A
- ZBH $25.00
- Revenue Growth
- NTRA 44.38
- ZBH 4.11
- 52 Week Low
- NTRA $110.57
- ZBH $89.22
- 52 Week High
- NTRA $183.00
- ZBH $116.71
- Technical
- Relative Strength Index (RSI)
- NTRA 65.28
- ZBH 67.08
- Support Level
- NTRA $152.62
- ZBH $101.56
- Resistance Level
- NTRA $161.92
- ZBH $103.57
- Average True Range (ATR)
- NTRA 6.11
- ZBH 2.30
- MACD
- NTRA 3.42
- ZBH 0.97
- Stochastic Oscillator
- NTRA 93.78
- ZBH 94.63
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About ZBH Zimmer Biomet Holdings Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.